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Abstract
Introduction: Interruption of sedation during weaning from mechanical ventilation often leads to patient agitation 
because of withdrawal syndrome. We tested the short-term efficacy and tolerance of loxapine in this situation.
Methods: Nineteen mechanically ventilated patients with marked agitation after sedation withdrawal were included. 
Three agitation scales, the Richmond Agitation Sedation Scale (RASS), the Motor Activity Assessment Scale (MAAS), and 
the Ramsay and physiological variables (respiratory rate, airway occlusion pressure during the first 0.1 second of 
inspiration (P0.1), heart rate and systolic arterial blood pressure) were recorded before and after loxapine 
administration.
Results: Loxapine dramatically improved all agitation scores (RASS and MASS decreased from 2 ± 0 to -1.1 ± 2.3, and 
5.4 ± 0.5 to 2.7 ± 1.6, respectively; Ramsay increased from 1.0 ± 0 to 3.5 ± 1.5, 60 minutes after loxapine administration, 
P < 0.05 for all scores) as well as P0.1 (6 ± 4.2 to 1.8 ± 1.8 cm H2O; P < 0.05) and respiratory rate (from 31.2 ± 7.2 to 23.4 ± 
7.8; P < 0.05) without hemodynamic adverse events. No side effects occurred. Sixteen (84%) patients were successfully 
managed with loxapine, sedation was resumed in two others, and one patient self-extubated without having to be 
reintubated.
Conclusions: Loxapine was safe and effective in treating agitation in a small group of mechanically ventilated patients 
and improved respiratory physiologic parameters, enabling the weaning process to be pursued. A multicenter trial is 
under way to confirm these promising results.
Introduction
ICU patients are constantly exposed to numerous nocice-
ptive stimuli during their ICU stays. Most of them require
appropriate sedation to maintain optimal levels of com-
fort and safety. This is particular true for patients with
respiratory failure who require invasive mechanical venti-
lation to optimize mechanical ventilation and to avoid
patient-ventilator asynchrony, especially during the acute
phase of respiratory distress. Once this phase is over,
efforts should be made to wean the patient from mechan-
ical ventilation as fast as possible to reduce the length of
invasive ventilation. Interruption of sedatives is an inevi-
table and necessary step in the weaning process. Weaning
does require, however, full cooperation of the patient.
The interruption of sedation at this period can lead to the
patient's agitation with benzodiazepine or opioid with-
drawal syndrome or both [1]. Risk factors for withdrawal
syndrome, such as alcoholism, a history of hypertension,
or the cumulative amount of sedative drugs have been
identified [2]. Moreover, withdrawal reactions may be
observed at the time of awakening in the setting of daily
interruption of sedative infusion [3]. Agitation carries
important proven side effects, such as increase in hospi-
talization duration [4], costs [5], long-term cognitive
impairment, and mortality [6]. It has also been suggested
that agitation could lead to weaning failure [7] and places
p a t i e n t s  a t  h i g h  r i s k  o f  s e l f  e x t u b a t i o n .  N o  c o n s e n s u s
exists concerning the management of agitation in this set-
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ting. Neuroleptic agents, such as haloperidol, have been
proposed as the first-line drugs to administer in combina-
tion with nonpharmacologic procedures such as environ-
mental control and psychological support [8]. Although
this drug is used in some ICUs, it can induce drowsiness
and decrease the patient's cooperation during the wean-
ing procedure. In addition, extrapyramidal syndromes
seem to occur more frequently after haloperidol than
after other antipsychotic drugs [9-11]. Eventually, a large
fraction of these patients are sedated again, leading finally
to an increased period of invasive mechanical ventilation.
Administration of loxapine, another neuroleptic agent,
could be an interesting option in this setting, because of
its good hemodynamic safety profile, its appropriate sed-
ative properties, the rarity of its side effects, and its low
cost. We, and those in many other ICUs in France, have
been using this drug routinely for years to treat agitation
[12], without ever precisely evaluating its sedative and
physiological effects in this setting. Therefore we evalu-
ated the short-term effects of loxapine on the agitation,
breathing pattern, and hemodynamics in agitated
patients during weaning from mechanical ventilation.
Materials and methods
Design and setting
This was a prospective single-center study in a university
hospital intensive care unit.
Patients
Inclusion criteria
Patients ventilated for >48 hours and considered poten-
tial candidates for weaning from the ventilator (resolu-
tion of the cause of acute respiratory failure, need for
<50% FiO2, and <5 cm H2O positive end-expiratory pres-
sure and hemodynamic stability according to SCCM
weaning guidelines [13]) were prospectively monitored at
the time of sedation (a combination of a benzodiazepine
and an opiate) decrease or withdrawal. Patients were eli-
gible for the study if they exhibited agitation after seda-
tion decrease or removal, defined by RASS >1 [14].
Exclusion criteria
Patients with contraindications to the enteral administra-
tion of drugs were not eligible for the study. Patients with
a known allergy to loxapine were excluded, along with
epilepsy patients (because of the risk of convulsions asso-
ciated with the use of neuroleptics).
Study drug administration
A first enteral administration of 150 mg of loxapine was
given via a nasogastric tube (that was already present for
f e e d i n g  o r  d r u g  a d m i n i s t r a t i o n  o r  b o t h ) .  I f  a g i t a t i o n
(defined by a RASS >1) recurred within 90 minutes, a sec-
ond administration of the same amount of loxapine was
given. If the RASS remained >1 despite the cumulative
dose of 300 mg, conventional sedation was resumed. The
patient remained eligible for a new evaluation during the
next attempt at sedation withdrawal.
Data
Baseline demographic data, indication for and duration of
mechanical ventilation, SAPS II [15], and the amounts of
sedative agents given in the previous 24 hours were regis-
tered. The RASS and two other agitation scales were
monitored: MAAS [16] and the Ramsay score [17]. We
also monitored the following physiological variables:
respiratory rate, heart rate, systolic arterial pressure, and
airway occlusion pressure during the first 0.1 seconds of
inspiration (P 0.1). This parameter was measured
through the automated procedure available on the respi-
rators used for this study (Evita 2 Dura, Evita 4, Evita
Excel; Dräger, Lübeck, Germany) and provided an indica-
tion on the magnitude of respiratory-drive normalization
provided by the study drug. All variables were monitored
before the withdrawal of sedatives, at the time of agita-
tion, and 60, 90, 120, and 180 minutes after initial admin-
istration of the study drug. Self-extubation or the
unexpected self-removal of the nasogastric cannula or
venous access were considered a failure of the drug, as
was persistent agitation defined by an RASS score >1.
The patients were closely screened for the following lox-
apine side effects: dyskinesia, extrapyramidal syndrome,
seizure, neuroleptic malignant syndrome (defined by ele-
vation of central temperature to >38°C, muscular rigidity,
altered mental status, and autonomic dysfunction, such
as unstable blood pressure or heart rate), and urinary
retention.
Ethical aspects
It has been usual practice for years in our ICU to admin-
ister loxapine to agitated mechanically ventilated
patients. The protocol did not require any change in the
dosage or the route of administration of the product. All
measurements were strictly noninvasive, including the
determination of P0.1, which was read from the respira-
tor.
Consent could not be obtained from patients by defini-
tion, given their agitation. Consent was sought from
proxies when they were present at the time of agitation.
Otherwise, proxies were informed of all the procedures.
Similarly, patients were informed of the details of the pro-
tocol as soon as their mental state allowed adequate com-
prehension. This protocol was approved by the Ethics
Committee of the French Intensive Care Society (Société
de Réanimation de Langue Française).
Statistical analysis
Results are expressed as mean ± standard deviation.
Changes over time of recorded variables were evaluated
with one-way analysis of variance (ANOVA) for repeatedSztrymf et al. Critical Care 2010, 14:R86
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measurements followed by Fisher's least significant dif-
ference test to detect differences between measurements.
A difference was considered significant when P < 0.05.
Results
Nineteen patients were included. Half of them had a his-
tory of chronic alcohol intake, as defined by drinking
more than the equivalent of 1 L of wine per day for sev-
eral years. Clinical characteristics, indication for mechan-
ical ventilation, according to Zwillich et al. [18], are
described in Table 1. The average dosage of midazolam
and sufentanyl administered to the patients in the previ-
ous 24 hours before inclusion was noticeable (Table 1).
Severe agitation was observed in the 19 patients after
sedation withdrawal, as attested to by impressive changes
in all three sedation/agitation scores, with marked
increases in both MASS and RASS and a similar decrease
in the Ramsay score (Figure 1). This agitation was accom-
panied by important increases in respiratory rate, P0.1,
heart rate, and systemic systolic arterial blood pressure
(Table 2 and Figure 2). All patients exhibited opioid or
benzodiazepine withdrawal syndrome or both, as defined
by Cammarano et al. [1].
Loxapine administration resulted in a dramatic
improvement of agitation in 17 of the 19 patients. Failure
of the drug occurred in two patients, despite the adminis-
tration of two 150-mg doses of loxapine, as indicated in
the protocol, and manifested as persistent agitation
(RASS = 2; MAAS >5; and Ramsay = 1). These two
patients required resumption of sedation to control the
agitation and were excluded from further analysis. No
agitation was observed when sedation was eventually dis-
continued, and both were successfully extubated after 2
and 4 additional days of ventilation, respectively. One of
the 17 patients in whom loxapine administration had pro-
vided adequate control of agitation self-extubated 90
minutes after the first administration. This patient
required no further ventilatory support and was dis-
charged from the ICU 2 days later. Thus, 16 patients were
available for analysis. The mean time between loxapine
administration and efficacy, defined by a significant
decrease in RASS, was 62 ± 39 minutes, during which, if
necessary, gentle physical restraints (under medical
supervision) and verbal reassuring were used while wait-
ing for the drug to be effective. All values for the agita-
tion/sedation scores were dramatically affected by
loxapine administration, as attested to by a return to lev-
els very close to those observed before agitation occurred
(Figure 1). More precisely, values for RASS after loxapine
administration were no longer different from those
observed before agitation, whereas values for both
MAAS and the Ramsay score were slightly, but signifi-
cantly, different from those observed before agitation,
indicating that patients were calm and cooperative but
less sedated than before agitation occurred. The changes
in respiratory pattern paralleled those of agitation seda-
tion scores (Figure 2). Indeed, both P0.1 and respiratory
rate dramatically decreased after loxapine administration
to become no different from values observed before agi-
tation for the former and only slightly higher for the lat-
ter. Heart rate and blood pressure decreased, but not
significantly, after loxapine administration (Table 2).
No side effect of lo xapine occurred in our cohort of
patients.
Discussion
Our study is the first to investigate the effects of loxapine
administration in patients developing agitation after
interruption of sedative drugs during weaning from inva-
sive mechanical ventilation. We found that loxapine sig-
nificantly reduced agitation in the vast majority of our
patients, was well tolerated, and provided a calm and
appropriate breathing pattern enabling the weaning pro-
cess, instead of our having to resedate the patients.
Table 1: Baseline characteristics of the patients
Age (years) 63.4 ± 13.2
Sex (m/f) 12/7
SAPS II 50 ± 9
Midazolam cumulative amount in the previous 24 hours (mg) 133 ± 128
Sufentanyl cumulative amount in the previous 24 hours (μg) 253 ± 225
Duration of MV (days) 10.4 ± 6.8
Indication for mechanical ventilationa Acute respiratory failure (n = 7)
Acute exacerbation of chronic respiratory impairment (n = 4)
Toxic coma (n = 4)
Sepsis (n = 3)
Postoperative respiratory failure (n = 1)
MV, mechanical ventilation; SAPS, simplified acute physiology score; m, male; f, female.
aAccording to reference [14].Sztrymf et al. Critical Care 2010, 14:R86
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Agitation is a common problem in the ICU and may
result from many different causes, including anxiety,
pain, delirium, withdrawal syndrome, shock, or respira-
tory distress. Because our patients' conditions had con-
siderably improved when weaning was started, we believe
that our patients were most likely agitated because of
benzodiazepine or opioid withdrawal syndrome or both.
Although we did not determine to what extent some may
have experienced delirium, the fact remains that their
mental status seriously compromised the weaning pro-
cess. The scope of this study was not to provide a precise
diagnosis for each encountered case but to study the
effect of loxapine on agitation (after excluding that agita-
tion was the result of a severe physical condition, that is,
shock, pneumothorax, and so on). Agitation is a complex
problem that may affect outcome. It has been shown that
agitation per se is associated with a prolonged ICU stay,
greater frequency of nosocomial infections, higher
unplanned extubations, and central venous catheter
removal rate, and a trend, although not significant,
toward a higher mortality in one study [19,20]. It must be
underlined that delirium was not monitored in these
studies, and that some of the included patients might
have exhibited agitation in the setting of delirium, with its
proven negative impact on survival [6]. In particular, agi-
tation impedes patient cooperation during weaning from
mechanical ventilation and very often leads to delayed
extubation. Undue prolongation of mechanical ventila-
tion favors the occurrence of complications such as venti-
lator-associated pneumonia [21] or disuse atrophy of
diaphragm [22] and increases hospital expenditures.
First-line treatment for agitation consists mainly of non-
pharmacologic interventions such as the establishment of
a comfortable and reassuring environment, but this may
not be sufficient in many instances. Sedative drug admin-
istration is thus often required to control agitation during
weaning, but few studies have adequately addressed this
issue [23]. Drugs aimed at controlling agitation during
weaning should exhibit a rapid and sustained efficacy on
neuropsychological disturbance with no or minimal
impairment of both consciousness and respiratory drive,
which would delay separation of the patient from the ven-
tilator. Haloperidol is recommended by some authors but
has numerous drawbacks, including extrapyramidal man-
ifestations and significant QTc interval prolongation [9-
11]. This drug was recently compared with a novel seda-
tive and anxiolytic agent, dexmedetomidine, in agitated
delirium [24]. In this open-label trial, dexmedetomidine
was found to shorten median time to extubation and to
reduce ICU length of stay in comparison with haloperi-
dol. Frequent cardiovascular and hemodynamic side
effects, such as bradycardia and hypotension, may, how-
ever, hinder the use of this promising agent [25]. Despite
others' and our very long experience with loxapine, few if
any prospective data exist on the use of loxapine in the
ICU. In our preliminary clinical experience, as well as in
that of others [12], loxapine characteristics and tolerance
seem appropriate for use in this indication.
Our study clearly indicates that loxapine seems safe and
efficient to treat agitation and allows a more physiologic
breathing pattern during weaning from mechanical venti-
lation. This was attested to by normalization of three agi-
tation/sedation scales, a dramatic improvement in the
respiratory pattern, and excellent hemodynamic toler-
ance. Our three agitation and sedation scales describe
awakening, anguish, agitation, and its subsequent threat
of the removal of tubes or catheters. Before agitation,
patients exhibited a state, described by RASS as 'light
sedation, patients briefly awakened with eyes contact to
voice,' by the Ramsay scale as 'patient with a brisk
response to stimulus,' and by MAAS as 'patients respon-
sive to touch or name with eyes opening or eyebrows rais-
ing or head turning when touched or name loudly
spoken.' At the onset of agitation, patients exhibited typi-
cal agitation patterns such as 'anxious, restless, moving
limbs out of the bed, fighting ventilator, attempting to sit
up.' Loxapine administration led to interruption of this
agitated state, with patients coming back to the previous
'light sedation status' or a cooperative state with 'sus-
tained awakening, orientated and tranquil, following
commands,' as described by the three scales. This dra-
matic improvement in sedation/agitation scores was par-
alleled by considerable decreases both in respiratory
drive activity and respiratory rate, which returned to val-
ues similar to those observed in calm patients breathing
spontaneously. Interestingly, these improvements were
obtained without any hemodynamic deterioration, as
Table 2: Effects of loxapine on hemodynamic parameters
Before agitation Agitation 60 minutes 90 minutes 120 minutes 180 minutes
HR (beats/min) 89.7 ± 15.6a 109.1 ± 19.4 108 ± 24.1 105.4 ± 24.2 108.9 ± 30.7 105.1 ± 25.3
SAP (mm Hg) 122.2 ± 22.1b 153.3 ± 29.3 136.8 ± 27.2 134.6 ± 26.2 136.8 ± 30.5 135.9 ± 27
aP < 0.0001 versus all other conditions.
bP < 0.005 versus value measured at the time of agitation.
HR, heart rate; SAP, systolic arterial pressure; beats/min, beats per minute.Sztrymf et al. Critical Care 2010, 14:R86
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indicated by stable heart rate and blood pressure (values
for this latter parameter were no different from those
measured before agitation occurred). No adverse reaction
to loxapine was observed during this study.
Airway-occlusion pressure has been used for assessing
output of the respiratory controller. It gives a measure-
ment of a weighted sum of the effect of all respiratory
muscles active at a given time and does not depend on the
resistance or compliance of the respiratory system [26]. It
has been suggested that this parameter is a sensitive and
nonspecific marker of weaning failure [27], an elevated
P0.1 meaning an increased inspiratory effort that might
not be sustained. Respiratory-drive inhibition was never
observed with 150 mg or in the two patients that required
a cumulative amount of 300 mg of loxapine.
As discussed earlier, we observed that loxapine exerted
its effects mainly on neuropsychic and respiratory distur-
bances, with few hemodynamic effects. Because with-
drawal syndrome is characterized by sympathetic
nervous system hyperactivity [28], adrenergic agonist
agents like clonidine were used for that indication, with a
certain degree of success [29]. It has been recognized that
adrenergic agonists' effect in withdrawal syndrome is
related to a decrease in sympathetic manifestations [28].
The targets of loxapine in the brain are dopamine and
serotonin-receptor subtypes [30], with few hemodynamic
Figure 1 Values for three sedation/agitation scores before agita-
tion, at the time of agitation, and at 60, 90, 120, and 180 minutes 
after loxapine (LXP) administration. Marked alteration of the three 
scores was initially observed. Loxapine administration resulted in nor-
malization of the three scores after 1 hour. This normalization persisted 
for several hours. Significance of differences: *P < 0.0001 versus all oth-
er conditions; † P < 0.005 versus all other conditions.
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Figure 2 Breathing-pattern scores before agitation, at the time of 
agitation, and at 60, 90, 120, and 180 minutes after loxapine (LXP) 
administration. The dramatic increase in both respiratory rate and 
P0.1 observed during agitation normalized after loxapine administra-
tion. Significance of differences: *P < 0.0001 versus all other conditions; 
† P < 0.05 versus values observed before agitation.
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effects, explaining why we observed no significant
changes in hemodynamic parameters after loxapine
administration. We hypothesize that the positive impact
of loxapine on the agitation scores is related to its effect
on anxiety and the observed decrease in respiratory rate.
This study is a preliminary physiological evaluation of
the acute, short-term effects and safety of loxapine during
weaning from mechanical ventilation in agitated patients.
Several limitations of this study deserve consideration.
First, loxapine did not allow adequate control of agitation
in all patients: indeed, sedation was resumed in two
patients because of persistent agitation despite two doses
of loxapine. An additional patient was apparently calm
after receiving loxapine but self-extubated during the
study, which might also be considered as a failure of the
drug. Nevertheless, loxapine was remarkably efficacious
in the remaining 16 (84%) patients. The small number of
patients in our study might have biased analysis of the
potential side effects of loxapine. We emphasize, how-
ever, that we and others in France have been using loxap-
ine for many years, without encountering noticeable side
effects. It must be underlined that we did not specifically
screen our patients for delirium. Therefore, although all
our patients exhibited withdrawal syndrome, other rea-
sons for agitation may have been present. The conse-
quences of this last point on the interpretation of the
results are unknown. Nonetheless, we were interested in
evaluating the symptomatic effect of loxapine rather than
investigating an etiologic treatment for agitation. In that
respect, our results suggest that loxapine was effective in
the vast majority of our patients.
Conclusions
In conclusion, our study shows that loxapine seems to be
safe and effective for treating acute agitation after with-
drawal of sedative infusions during weaning from
mechanical ventilation. It has a positive and sustained
effect on several neurologic and respiratory disturbed
parameters during withdrawal syndrome, enabling us to
pursue the weaning process. Our results constitute the
prerequisite for a randomized controlled study of the
effects of loxapine on the duration of weaning in agitated
mechanically ventilated patients. We are currently under-
taking such a study.
Key messages
• Agitation in the setting of withdrawal syndrome
impedes patient cooperation during weaning from
mechanical ventilation and often leads to delayed extuba-
tion.
• Loxapine has a positive effect on neurologic and
respiratory disturbed parameters during withdrawal syn-
drome.
• Our study shows that loxapine seems to be safe and
efficient for treating acute agitation during mechanical
ventilation weaning after the withdrawal of sedative infu-
sions.
• Further data are required to test the effect of loxapine
on the duration of weaning.
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